Delpharm is a pharmaceutical contract manufacturing organization based in France. Established in 1994, the company has quickly grown to become one of the leading players in the industry, providing a wide range of services to the pharmaceutical sector. The company's headquarters are located in Tours, France.

Spread over 20,000 square meters, it houses state-of-the-art manufacturing and packaging facilities. The headquarters also serve as the central hub for the company's research and development activities. Delpharm offers a comprehensive range of services, including contract manufacturing, contract development, and packaging of pharmaceutical products.

The company specializes in various dosage forms such as tablets, capsules, liquids, creams, and injectables. Delpharm's expertise lies in handling both highly potent and non-potent drugs, allowing them to cater to a diverse range of client needs. On a global scale, Delpharm operates through a network of subsidiaries, joint ventures, and partnerships.

The company has established subsidiaries in several countries, including Belgium, Germany, Italy, and the UK, which enable them to offer localized manufacturing and distribution services to their clients. In terms of market position, Delpharm is recognized as a key player in the contract manufacturing industry. The company consistently ranks among the top contract manufacturers globally, with significant sales figures and a solid reputation for quality and reliability.

Delpharm's expertise in offering cost-effective solutions and its ability to handle complex manufacturing processes have positioned it as a preferred partner for pharmaceutical companies worldwide. Over the years, Delpharm has achieved several noteworthy milestones and partnerships that have contributed to its growth. In 2018, the company partnered with Expanscience Laboratories to manufacture and market their injectable hyaluronic acid-based products.

This collaboration expanded Delpharm's product portfolio and strengthened its presence in the dermatology and cosmetics sectors. Currently, Delpharm continues to strengthen its market position and expand its global footprint. The company remains committed to investing in cutting-edge technologies and is consistently involved in research and development activities to enhance its service offerings.

With its strong reputation and ongoing commitment to innovation, Delpharm is well positioned for continued success in the pharmaceutical contract manufacturing industry